FDA expects Ranbaxy immediately to undertake a comprehensive assessment of its global manufacturing operations to ensure all sites manufacturing drugs for the US market conform to US requirements," the warning letter had said. In 2011, the Ranbaxy management decided to close the Gloversville unit. Then Managing Director Arun Sawhney had said it was operating at a "sub-optimal level". Ranbaxy says its manufacturing facilities in India and other parts of the world are routinely inspected by leading global regulatory agencies. Since 2009, the company has undergone at least 175 regulatory agency inspections across its global facilities, it added. BAD MEDICINE